Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
More isn't better if the delivery system can't support it
The TRIUMPH-4 trial showed that retatrutide at 12mg reduced: Systolic blood pressure: 14.0 mmHg reduction Non-HDL cholesterol: clinically meaningful improvement High-sensitivity C-reactive protein: significant reduction (a marker of systemic inflammation) Triglycerides: substantial decrease Tirzepatide produces similar cardiovascular improvements, with well-documented reductions in blood pressure, triglycerides, and inflammatory markers across the SURMOUNT and SURPASS programs
95%CI = 1.02-2.45
Further, in vitro evidence (72) shows that urolithin A and its phase-II metabolites can cross the bloodbrain barrier, an ability that would be necessary for their direct effects in the brain
Because both participants and investigators knew which treatment was being administered, the trial introduced a degree of bias that does not affect the blinded pivotal trials
US$ 24.86
US$ 29.51
US$ 28.10
US$ 25.83
US$ 28.56
US$ 25.26
US$ 20.09
US$ 20.41
US$ 22.49
US$ 25.30
US$ 26.29
